Hong Kong's new drug regulator to launch with 21 approvals already secured

For healthcare providers and patients in Hong Kong, the shift from a laggard to a leader in drug approvals could dramatically reduce wait times for novel therapies. With 21 drugs already approved under a streamlined mechanism and a full regulatory body launching in Q4 2026, the city is poised to offer faster access to cutting-edge treatments, potentially transforming care for cancer, rare diseases, and chronic conditions.

Hong Kong is set to transform its pharmaceutical regulatory landscape with the launch of its own Centre for Medical Products Regulation (CMPR) by the fourth quarter of 2026, as revealed by Secretary for Health Lo Chung-mau in an exclusive interview with the South China Morning Post. This marks a pivotal shift from the city’s historically passive approach—where drug registration required prior approval from two other jurisdictions—to a proactive, primary evaluation model. The CMPR is not merely a bureaucratic addition; it is the cornerstone of Hong Kong’s ambition to become an international biomedical hub, aligning with national policies and the Greater Bay Area’s development momentum.

“

The CMPR is not merely a bureaucratic addition; it is the cornerstone of Hong Kong’s ambition to become an international biomedical hub, aligning with national policies and the Greater Bay Area’s development momentum.

The global talent hunt accompanying the CMPR launch underscores the scale of the undertaking. Lo emphasized the need to attract regulatory scientists, clinical assessors, and pharmacovigilance experts from around the world, a bid to quickly build in-house evaluation capacity. This recruitment effort is coupled with ongoing negotiations with mainland China to secure World Health Organization (WHO) recognition for the CMPR—a crucial stamp of legitimacy that would allow the city to become a listed authority under the WHO’s collaborative registration scheme. Such recognition would not only shorten drug approval timelines but also enhance Hong Kong’s standing as a trusted first-stop evaluator for innovative therapies, potentially attracting pharmaceutical investment and clinical trial activities.

The timeline for this regulatory evolution is already in motion. Since November 2023, the government has been piloting an interim '1+' mechanism, which permits drug registration based on local clinical data plus one foreign approval, down from the previous two. The results are tangible: 21 drugs have been approved through this pathway, demonstrating the viability of a streamlined process. These approvals have in turn encouraged pharmaceutical companies to broaden their Hong Kong operations beyond sales into clinical data collection and regulatory engagement—a crucial step toward building a robust local biomedical ecosystem.

The implications for Hong Kong’s healthcare system and economy are multifaceted. For patients, reduced approval times could mean faster access to cutting-edge treatments, particularly in areas like oncology, rare diseases, and advanced biologics. For the pharmaceutical industry, especially biotech companies with innovative pipelines, Hong Kong could become a gateway to the Greater Bay Area’s market of over 86 million people. The CMPR’s emergence also dovetails with China’s broader regulatory reforms, potentially harmonizing standards across the region while preserving Hong Kong’s distinct legal and quality frameworks.